Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence
Vol. 6 No. 1 (2022), Kritikoki Aztertutako Testuak
Vol. 6 No. 1 (2022)

Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence

Kritikoki Aztertutako Testuak
Published 2022-07-29
Asier Mitxelena
Osakidetza
Maria Areses
Osakidetza
PDF (Euskara)

Keywords

Bezlotoxumab
diarrhea
Clostridium Difficile
toxin
antitoxin

How to Cite

Mitxelena, A., & Areses, M. (2022). Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence. Osagaiz: Osasun-Zientzien Aldizkaria, 6(1). Retrieved from https://aldizkariak.ueu.eus/index.php/osagaiz/article/view/362
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Compared to placebo, Bezlotoxumab reduces 10% the risk of recurrence of Clostridium Difficile (17% vs 27%; 95% CI: -15 to -4) in MODIFY I trial, and very similar results are obtained in MODIFY II trial (-10%; 16% vs 26%; 95% CI: -15 to -4). The addition of actoxumab to bezlotoxumab did not improve efficacy (-11%; 16% vs 28%; 95% CI: -17 to -6).

PDF (Euskara)

Most read articles by the same author(s)